Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001303903 | SCV001493169 | uncertain significance | Multiple gastrointestinal atresias | 2021-08-27 | criteria provided, single submitter | clinical testing | This sequence change replaces phenylalanine with leucine at codon 279 of the TTC7A protein (p.Phe279Leu). The phenylalanine residue is moderately conserved and there is a small physicochemical difference between phenylalanine and leucine. This variant is present in population databases (rs760569935, ExAC 0.001%). This variant has not been reported in the literature in individuals affected with TTC7A-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002539536 | SCV003725825 | uncertain significance | Inborn genetic diseases | 2022-11-08 | criteria provided, single submitter | clinical testing | The c.837C>A (p.F279L) alteration is located in exon 6 (coding exon 6) of the TTC7A gene. This alteration results from a C to A substitution at nucleotide position 837, causing the phenylalanine (F) at amino acid position 279 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |